Gene therapy for IGHMBP2-related nerve conditions
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This early-phase study tests a gene therapy meant to treat people who have IGHMBP2 gene changes. It aims to improve the way the nervous system works and to see if the treatment is safe, especially in young children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have two confirmed IGHMBP2 gene changes from a CLIA-certified lab test
- Your age/mobility fits one of these: not yet walking (under 18 months), or able to walk 10 meters with little/no help, or unable to walk more than 10 meters on your own
- You can participate in required check-ups and movement/function testing
- You have not had any prior gene or cell therapy treatment (of any kind)
- You do not have recent immunizations in the month before starting the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy for people with a specific mutation (S295L) in the SLC6A1 gene, which causes a neurodevelopmental disorder. The therapy aims to correct the genetic issue, and participants will be monitored closely for safety and effectiveness.
This trial tests a gene-transfer treatment (delivered into the spinal fluid) for children with MPS IIIA, a rare genetic condition. It aims to improve or slow down brain and developmental changes caused by a missing enzyme.
This early-stage study tests an IV gene therapy that delivers a working copy of an enzyme gene to help the body make beta-galactosidase in GM1 gangliosidosis. It may help slow or improve disease symptoms and looks closely at safety and how well the treatment works.
This early-stage study tests whether a one-time gene therapy can safely improve outcomes for babies with the most severe type of spinal muscular atrophy (SMA type 1). It focuses on safety and early signs of benefit, and participation requires specific genetic and health criteria.
This trial tests a new gene therapy called GCB-001 for children with type 2 spinal muscular atrophy who can sit but not walk. It aims to improve muscle function and overall health.
This trial tests whether giving a gene therapy before birth can help babies with GM1 gangliosidosis, a rare genetic disorder that damages the brain and body. It uses a harmless virus to deliver a working copy of the missing enzyme, aiming to slow or prevent disease progression.
Hear when a new SMARD1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.